Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary...
February 24, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary...
February 05, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary...
January 28, 2025 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Announces 1-for-80 Reverse Stock Split

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet...
January 15, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company, today announced that the two leading independent proxy...
January 06, 2025 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet...
December 06, 2024 08:00 ET | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
November 25, 2024 08:00 ET | Source: Eyenovia, Inc.

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
November 22, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Provides Update on Restructuring Efforts

Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic...
November 15, 2024 07:00 ET | Source: Eyenovia, Inc.

Eyenovia Provides Update on Phase 3 CHAPERONE Study

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and...